• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发一种灵敏的 HPLC 方法,用于测量 Caco-2 单层细胞中外消旋和 Z 异构体形式的硫代卡巴肼的体外渗透性。

Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers.

机构信息

Center for Sickle Cell Disease, Department of Medicine, Howard University College of Medicine, Washington, DC, United States.

出版信息

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 1;906:25-32. doi: 10.1016/j.jchromb.2012.08.011. Epub 2012 Aug 15.

DOI:10.1016/j.jchromb.2012.08.011
PMID:22954966
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3457786/
Abstract

In the current study, we developed a HPLC method to quantitatively measure the permeability of the BpT-based chelators, 2-benzoylpyridine 4-ethyl-3-thiosemicarbazone (Bp4eT) and 2-benzoylpyridine 4-allyl-3-thiosemicarbazone (Bp4aT), across human colorectal adenocarcinoma (Caco-2) monolayers as a model of gut absorption. In aqueous solution, Bp4eT and Bp4aT formed inter-convertible Z and E isomers that were resolved by HPLC. Peak area was linear with respect to chelator concentration. Acceptable within-day and between-day precision (<22%) and accuracy (85-115% of true values) were obtained over a range of 1.0-100μM for Bp4eT and 1.5-300μM for Bp4aT. Limits of detection were 0.3μM and 1μM for Bp4eT and Bp4aT, respectively, while corresponding limits of quantification were 1μM and 5μM. Both chelators showed significant ability to chelate iron in THP-1 cells using a calcein-based assay and no apparent cytotoxicity was observed within 24h. Ratios of the apical to basolateral and basolateral to apical transport for Bp4eT were 1.10 and 0.89 at 100μM and 300μM respectively, indicating equal bi-directional movement of the compounds. Similarly, ratios were 0.77 and 0.92 for Bp4aT, respectively. This study demonstrates that Bp4eT and Bp4aT can be efficiently transported through Caco-2 cells and can potentially be formulated for oral delivery.

摘要

在本研究中,我们开发了一种 HPLC 方法来定量测量基于 BpT 的螯合剂 2-苯甲酰基吡啶 4-乙基-3-硫代缩氨基脲(Bp4eT)和 2-苯甲酰基吡啶 4-烯丙基-3-硫代缩氨基脲(Bp4aT)在人结直肠腺癌细胞(Caco-2)单层作为肠道吸收模型中的渗透性。在水溶液中,Bp4eT 和 Bp4aT 形成可相互转化的 Z 和 E 异构体,可通过 HPLC 分离。峰面积与螯合剂浓度呈线性关系。在 1.0-100μM 范围内,Bp4eT 的日内和日间精密度(<22%)和准确度(真实值的 85-115%)均可接受,Bp4aT 的日内和日间精密度(<22%)和准确度(真实值的 85-115%)均可接受,Bp4aT 的日内和日间精密度(<22%)和准确度(真实值的 85-115%)均可接受,Bp4aT 的范围为 1.5-300μM。Bp4eT 和 Bp4aT 的检测限分别为 0.3μM 和 1μM,定量限分别为 1μM 和 5μM。两种螯合剂在使用钙黄绿素测定法测定 THP-1 细胞中铁的螯合能力方面均表现出显著的能力,并且在 24 小时内未观察到明显的细胞毒性。在 100μM 和 300μM 时,Bp4eT 的顶端至基底侧和基底侧至顶端转运的比率分别为 1.10 和 0.89,表明化合物的双向运动相等。同样,Bp4aT 的比率分别为 0.77 和 0.92。本研究表明,Bp4eT 和 Bp4aT 可有效穿过 Caco-2 细胞转运,并且可能可被制成口服剂型。

相似文献

1
Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers.开发一种灵敏的 HPLC 方法,用于测量 Caco-2 单层细胞中外消旋和 Z 异构体形式的硫代卡巴肼的体外渗透性。
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 1;906:25-32. doi: 10.1016/j.jchromb.2012.08.011. Epub 2012 Aug 15.
2
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9.二吡啶酮缩硫代氨基脲和 2-苯甲酰基吡啶缩硫代氨基脲系列的铁螯合剂抑制 HIV-1 转录:新型细胞靶标的鉴定——铁、细胞周期蛋白依赖性激酶(CDK)2 和 CDK9。
Mol Pharmacol. 2011 Jan;79(1):185-96. doi: 10.1124/mol.110.069062. Epub 2010 Oct 18.
3
In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites.抗癌螯合剂Bp4eT及其I期代谢产物药理特性的体外表征
PLoS One. 2015 Oct 13;10(10):e0139929. doi: 10.1371/journal.pone.0139929. eCollection 2015.
4
Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer.新型硫代氨基甲肟螯合剂的跨膜转运和细胞内隔离及其在癌症治疗中的应用。
Mol Pharmacol. 2010 Oct;78(4):675-84. doi: 10.1124/mol.110.066126. Epub 2010 Jul 6.
5
Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT.建立一种 LC-MS/MS 方法,用于分析新型抗癌药物 Bp4eT 的可互变 Z/E 异构体。
Anal Bioanal Chem. 2010 May;397(1):161-171. doi: 10.1007/s00216-009-3448-7. Epub 2010 Feb 2.
6
Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats.同时测定新型硫代氨基脲抗癌剂Bp4eT及其在血浆中的主要I期代谢物:应用于大鼠的初步药代动力学研究。
Biomed Chromatogr. 2014 May;28(5):621-9. doi: 10.1002/bmc.3080. Epub 2013 Nov 20.
7
Synthesis and biological evaluation of 2-benzoylpyridine thiosemicarbazones in a dimeric system: structure-activity relationship studies on their anti-proliferative and iron chelation efficacy.二聚体体系中2-苯甲酰基吡啶硫代半卡巴腙的合成与生物学评价:其抗增殖和铁螯合功效的构效关系研究
J Inorg Biochem. 2014 Dec;141:43-54. doi: 10.1016/j.jinorgbio.2014.07.020. Epub 2014 Aug 7.
8
Caco-2 cell permeability of a new (hydroxybenzyl)ethylenediamine oral iron chelator: correlation with physicochemical properties and oral activity.一种新型(羟基苄基)乙二胺口服铁螯合剂的Caco-2细胞通透性:与理化性质及口服活性的相关性
J Pharm Sci. 1998 Sep;87(9):1041-5. doi: 10.1021/js980191s.
9
Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.基于喹啉的缩氨基硫脲的合成与表征及其与细胞内铁结合效力与抗肿瘤效力的相关性。
Bioorg Med Chem Lett. 2012 Sep 1;22(17):5527-31. doi: 10.1016/j.bmcl.2012.07.030. Epub 2012 Jul 15.
10
Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.新型铁螯合剂的设计、合成与表征:2-苯甲酰基吡啶硫代半卡巴腙系列及其3-硝基苯甲酰类似物作为强效抗肿瘤剂的构效关系
J Med Chem. 2007 Jul 26;50(15):3716-29. doi: 10.1021/jm070445z. Epub 2007 Jun 30.

引用本文的文献

1
Synthesis and Antibacterial Activity of Novel Hydroxy Semicarbazone Derivatives.新型羟基缩氨基脲衍生物的合成与抗菌活性
Iran J Pharm Res. 2016 Winter;15(Suppl):29-35.
2
In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites.抗癌螯合剂Bp4eT及其I期代谢产物药理特性的体外表征
PLoS One. 2015 Oct 13;10(10):e0139929. doi: 10.1371/journal.pone.0139929. eCollection 2015.
3
A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate--ZMC1.一种用于新型抗癌候选药物——ZMC1的灵敏液相色谱-质谱生物分析方法。
Biomed Chromatogr. 2015 Nov;29(11):1708-14. doi: 10.1002/bmc.3483. Epub 2015 May 5.
4
Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase IκB-α expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription.基于苯基-1-吡啶-2-基-乙酮的铁螯合剂可增加IκB-α表达,调节CDK2和CDK9活性,并抑制HIV-1转录。
Antimicrob Agents Chemother. 2014 Nov;58(11):6558-71. doi: 10.1128/AAC.02918-14. Epub 2014 Aug 25.

本文引用的文献

1
[Iron homeostasis, a defense mechanism in oxidative stress].[铁稳态,氧化应激中的一种防御机制]
Postepy Biochem. 2010;56(3):305-16.
2
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9.二吡啶酮缩硫代氨基脲和 2-苯甲酰基吡啶缩硫代氨基脲系列的铁螯合剂抑制 HIV-1 转录:新型细胞靶标的鉴定——铁、细胞周期蛋白依赖性激酶(CDK)2 和 CDK9。
Mol Pharmacol. 2011 Jan;79(1):185-96. doi: 10.1124/mol.110.069062. Epub 2010 Oct 18.
3
Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity.新型 ApT 和 DpT 系列硫代卡巴腙及其铜配合物:显著氧化还原活性的鉴定及其抗肿瘤活性的表征。
J Med Chem. 2010 Aug 12;53(15):5759-69. doi: 10.1021/jm100561b.
4
Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT.建立一种 LC-MS/MS 方法,用于分析新型抗癌药物 Bp4eT 的可互变 Z/E 异构体。
Anal Bioanal Chem. 2010 May;397(1):161-171. doi: 10.1007/s00216-009-3448-7. Epub 2010 Feb 2.
5
Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.环吡酮胺和去铁酮抑制 HIV-1 基因表达,这两种药物可防止真核起始因子 5A 的超氨化。
Retrovirology. 2009 Oct 13;6:90. doi: 10.1186/1742-4690-6-90.
6
An extended-release formulation of desferrioxamine for subcutaneous administration.一种用于皮下给药的去铁胺延长释放制剂。
Drug Deliv. 2009 Oct;16(7):416-21. doi: 10.1080/10717540903141768.
7
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.从旧到新的硫代氨基脲类化合物:不仅仅是核糖核苷酸还原酶抑制剂的铁螯合剂。
J Med Chem. 2009 Sep 10;52(17):5271-94. doi: 10.1021/jm900552r.
8
HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents.高效液相色谱法测定血浆中两种新型硫代氨基脲类抗癌药物(N4mT和Dp44mT)及其在这些药物体外血浆稳定性研究中的应用
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):316-22. doi: 10.1016/j.jchromb.2008.11.044. Epub 2008 Dec 6.
9
Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.具有抗增殖活性的新型铁螯合剂的设计、合成与表征:新型硫腙类似物的构效关系
J Med Chem. 2007 Nov 29;50(24):6212-25. doi: 10.1021/jm070839q. Epub 2007 Oct 27.
10
Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study.Caco-2细胞单层中溶质的渗透性、转运和代谢:一项理论研究。
Drug Metab Dispos. 2008 Jan;36(1):102-23. doi: 10.1124/dmd.107.015321. Epub 2007 Oct 11.